{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:45:52Z","timestamp":1792165552651,"version":"4.4.0"},"reference-count":94,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>The evolution of personalized medicine in dermatology signifies a transformative shift towards individualized treatments, driven by the integration of biomarkers. These molecular indicators serve beyond diagnostics, offering insights into disease staging, prognosis, and therapeutic monitoring. Specific criteria guide biomarker selection, ensuring attributes like specificity, sensitivity, cost feasibility, stability, rapid detection, and reproducibility. This literature review, based on data from PubMed, SCOPUS, and Web of Science, explores biomarkers in Hidradenitis Suppurativa (HS), Psoriasis, Atopic Dermatitis (AD), Alopecia Areata (AA), Vitiligo, and Chronic Spontaneous Urticaria (CSU). In HS, TNF-\u03b1, IL-1\u03b2, and MMPs serve as biomarkers, influencing targeted therapies like adalimumab and anakinra. Psoriasis involves biomarkers such as TNF-\u03b1, IL-23, and HLA genes, shaping treatments like IL23 and IL17 inhibitors. AD biomarkers include ECP, IL-4, IL-13, guiding therapies like dupilumab and tralokinumab. For AA, lipocalin-2, cytokines, and genetic polymorphisms inform JAK inhibitors\u2019 use. Vitiligo biomarkers range from cytokines to genetic markers like TYR, TYRP1, guiding treatments like JAK inhibitors. CSU biomarkers encompass IgE, cytokines, and autologous serum tests, influencing therapies like omalizumab and cyclosporine. Comparing conditions, common proinflammatory markers reveal limited specificity. While some biomarkers aid diagnosis and standard treatments, others hold more scientific than clinical value. Precision medicine, driven by biomarkers, has shown success in skin malignancies. Future directions involve AI-powered algorithms, nanotechnology, and multi-omics integration for personalized dermatological care.<\/jats:p>","DOI":"10.3390\/cimb46040186","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T07:18:28Z","timestamp":1711955908000},"page":"2975-2990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies"],"prefix":"10.3390","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-6609","authenticated-orcid":false,"given":"Isabella J.","family":"Tan","sequence":"first","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, 125 Paterson Steet, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5109-2405","authenticated-orcid":false,"given":"Alicia","family":"Podwojniak","sequence":"additional","affiliation":[{"name":"Rowan-Virtua School of Osteopathic Medicine, 113 E Laurel Road, Stratford, NJ 08084, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarushi","family":"Parikh","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, 125 Paterson Steet, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.gpb.2015.04.002","article-title":"Biomarkers of An Autoimmune Skin Disease\u2013Psoriasis","volume":"13","author":"Jiang","year":"2015","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1028694","DOI":"10.3389\/fmed.2022.1028694","article-title":"Potential biomarkers of atopic dermatitis","volume":"9","author":"Yu","year":"2022","journal-title":"Front. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"879754","DOI":"10.3389\/fimmu.2022.879754","article-title":"The Role of Crosstalk of Immune Cells in Pathogenesis of Chronic Spontaneous Urticaria","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chen, H., Wang, X., Han, J., Fan, Z., Sadia, S., Zhang, R., Guo, Y., Jiang, Y., and Wu, Y. (2017). AKT and its related molecular feature in aged mice skin. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178969"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/exd.12948","article-title":"Biomarkers and personalized medicine: Current status and further perspectives with special focus on dermatology","volume":"25","author":"Landeck","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e139932","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and Safety of Adalimumab in Conjunction with Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ocker, L., Abu Rached, N., Seifert, C., Scheel, C., and Bechara, F.G. (2022). Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11237240"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","article-title":"Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review","volume":"158","author":"Hessam","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: A scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3892\/etm.2021.11075","article-title":"Cardiovascular comorbidities in psoriasis (Review)","volume":"23","author":"Branisteanu","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tokuyama, M., and Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207488"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2019.11.027","article-title":"Molecular and Cellular Responses to the TYK2\/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis","volume":"140","author":"Page","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2133.1992.tb00677.x","article-title":"Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis","volume":"126","author":"Czech","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kim, K., Kim, H., and Sung, G.Y. (2022). An Interleukin-4 and Interleukin-13 Induced Atopic Dermatitis Human Skin Equivalent Model by a Skin-On-A-Chip. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042116"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7697699","DOI":"10.1155\/2023\/7697699","article-title":"The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target","volume":"2023","author":"Luo","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Moosbrugger-Martinz, V., Leprince, C., M\u00e9chin, M.-C., Simon, M., Blunder, S., Gruber, R., and Dubrac, S. (2022). Revisiting the Roles of Filaggrin in Atopic Dermatitis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105318"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2332\/allergolint.10-OA-0297","article-title":"Periostin contributes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes","volume":"61","author":"Shiraishi","year":"2012","journal-title":"Allergol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: A new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council","volume":"147","author":"Thyssen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term Efficacy of Baricitinib in Adults with Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Orfali, R.L., and Aoki, V. (2023). Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020577"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wa\u015bkiel-Burnat, A., Niemczyk, A., Chmieli\u0144ska, P., Muszel, M., Zaremba, M., Rakowska, A., Olszewska, M., and Rudnicka, L. (2022). Lipocalin-2 and insulin as new biomarkers of alopecia areata. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268086"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103339","DOI":"10.1016\/j.autrev.2023.103339","article-title":"Biomarkers in alopecia Areata: A systematic review and meta-analysis","volume":"22","author":"Zaaroura","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/1354750X.2022.2046855","article-title":"Association of CTLA-4 gene polymorphisms and alopecia areata: A systematic review and meta-analysis","volume":"27","author":"Zhou","year":"2022","journal-title":"Biomarkers"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gil-Qui\u00f1ones, S.R., Sep\u00falveda-Pach\u00f3n, I.T., Vanegas, G.S., and Gutierrez-Casta\u00f1eda, L.D. (2021). Effect of PTPN22, FAS\/FASL, IL2RA and CTLA4 genetic polymorphisms on the risk of developing alopecia areata: A systematic review of the literature and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0258499"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Pavel","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","first-page":"e89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Jabbari","year":"2016","journal-title":"JCI Insight"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"950450","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1111\/jocd.14844","article-title":"Intralesional vitamin D3 in treatment of alopecia areata: A randomized controlled clinical trial","volume":"21","author":"Rashad","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.autrev.2017.07.005","article-title":"Biomarkers of disease activity in vitiligo: A systematic review","volume":"16","author":"Speeckaert","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/21655979.2021.1933743","article-title":"Identification of TYR, TYRP1, DCT and LARP7 as related biomarkers and immune infiltration characteristics of vitiligo via comprehensive strategies","volume":"12","author":"Zhang","year":"2021","journal-title":"Bioengineered"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/CCID.S443165","article-title":"Identification of Dopachrome Tautomerase (DCT) and Kinesin Family Member 1A (KIF1A) as Related Biomarkers and Immune Infiltration Characteristics of Vitiligo Based on Lasso-SVM Algorithms","volume":"16","author":"Zhao","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_43","first-page":"8265","article-title":"Soluble CD27 and MIF as possible serum biomarkers of vitiligo activity in Egyptian patients in Sharkia Governorate","volume":"11","author":"ElMokadem","year":"2019","journal-title":"Dermatol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jdermsci.2004.08.007","article-title":"Role of macrophage migration inhibitory factor (MIF) in the skin","volume":"37","author":"Shimizu","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1468-3083.2007.02228.x","article-title":"Autoimmunity as an aetiologic factor in vitiligo","volume":"21","author":"Rezaei","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"Konijnenberg","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1590\/S0100-879X2012007500152","article-title":"Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and activity in vitiligo vulgaris","volume":"46","author":"Ma","year":"2013","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2230.2009.03617.x","article-title":"A Macrophage migration inhibitory factor in patients with vitiligo and relationship between duration and clinical type of disease","volume":"35","author":"Serarslan","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jamadermatol.2016.2366","article-title":"Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo","volume":"152","author":"Speeckaert","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12577","article-title":"Alarmins and immunity","volume":"280","author":"Yang","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1069196","DOI":"10.3389\/fimmu.2022.1069196","article-title":"Circulatory levels of alarmins in patients with non-segmental vitiligo: Potential biomarkers for disease diagnosis and activity\/severity assessment","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jid.2017.01.033","article-title":"S100B is a potential disease activity marker in nonsegmental vitiligo","volume":"137","author":"Speeckaert","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijd.ijd_27_22","article-title":"A Cross-Sectional Study of the Levels of Cytokines IL-6, TNF-\u03b1, and IFN-\u03b3 in Blood and Skin (Lesional and Uninvolved) of Vitiligo Patients and their Possible Role as Biomarkers","volume":"68","author":"De","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13526","DOI":"10.1038\/s41598-022-17770-3","article-title":"Investigating melanogenesis-related microRNAs as disease biomarkers in vitiligo","volume":"12","author":"Abdallah","year":"2022","journal-title":"Sci Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41598-020-58949-w","article-title":"Author Correction: Micro RNAs upregulated in Vitiligo skin play an important role in its aetiopathogenesis by altering TRP1 expression and keratinocyte-melanocytes cross-talk","volume":"10","author":"Vaish","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/1346-8138.13886","article-title":"Altered expression of four mi RNA (miR-1238-3p, miR-202-3p, miR-630 and miR-766-3p) and their potential targets in peripheral blood from vitiligo patients","volume":"44","author":"Shang","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4103\/ijd.ijd_917_20","article-title":"Assessment of Oxidative\/Nitrosative Stress and Raftlin in Vitiligo","volume":"67","author":"Mulayim","year":"2022","journal-title":"Indian J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11882-023-01117-7","article-title":"Biomarkers of Autoimmune Chronic Spontaneous Urticaria","volume":"23","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4168\/aair.2021.13.2.206","article-title":"Total IgE as a Marker for Chronic Spontaneous Urticaria","volume":"13","author":"Altrichter","year":"2021","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jdv.14221","article-title":"Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria","volume":"31","author":"Maurer","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e13727","DOI":"10.1111\/pai.13727","article-title":"Biomarkers associated with chronic spontaneous urticaria severity in 108 children","volume":"33","author":"Zhang","year":"2022","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e12290","DOI":"10.1002\/clt2.12290","article-title":"In chronic spontaneous urticaria, IgE and C-reactive protein are linked to distinct microRNAs and interleukin-31","volume":"13","author":"Demir","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.5114\/ada.2021.112276","article-title":"Biomarkers of disease activity in patients with chronic spontaneous urticaria","volume":"38","author":"Plavsic","year":"2021","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_65","first-page":"44","article-title":"Efficacy and Safety of Up-dosed Second-generation Antihistamines in Uncontrolled Chronic Spontaneous Urticaria: A Review","volume":"16","author":"Podder","year":"2023","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Maronese, C.A., Ferrucci, S.M., Moltrasio, C., Lorini, M., Carbonelli, V., Asero, R., Marzano, A.V., and Cugno, M. (2023). IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010378"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/jdv.12831","article-title":"Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels","volume":"30","author":"Altrichter","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000453453","article-title":"D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria","volume":"172","author":"Asero","year":"2017","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jdv.15350","article-title":"Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: A study of 470 patients","volume":"33","author":"Marzano","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaci.2014.11.016","article-title":"Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria","volume":"135","author":"Asero","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.23822\/EurAnnACI.1764-1489.05","article-title":"CRP, D-Dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria","volume":"49","author":"Kolkhir","year":"2017","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","article-title":"Association between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis","volume":"11","author":"Chuang","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.5415\/apallergy.2020.10.e12","article-title":"Relationship between changes in the 7-day urticaria activity score after treatment with omalizumab and the responsiveness of basophils to Fc\u03b5RI stimulation in patients with chronic spontaneous urticaria","volume":"10","author":"Endo","year":"2020","journal-title":"Asia Pac. Allergy"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/all.13352","article-title":"C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria","volume":"73","author":"Kolkhir","year":"2018","journal-title":"Allergy"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2500\/aap.2019.40.4230","article-title":"Factors related to omalizumab resistance in chronic spontaneous urticaria","volume":"40","author":"Magen","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.23822\/EurAnnACI.1764-1489.132","article-title":"Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria","volume":"53","author":"Darrigade","year":"2021","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000534662","article-title":"Biomarkers of Autologous Whole Blood Injection Efficacy in Patients with Chronic Spontaneous Urticaria with Autoreactivity: A Preliminary Study","volume":"185","author":"Chen","year":"2024","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.celrep.2015.12.041","article-title":"Compartmentalized Epidermal Activation of \u03b2-Catenin Differentially Affects Lineage Reprogramming and Underlies Tumor Heterogeneity","volume":"14","author":"Kretzschmar","year":"2016","journal-title":"Cell Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"14091","DOI":"10.1038\/ncomms14091","article-title":"Macrophages induce AKT\/\u03b2-catenin-dependent Lgr5+ stem cell activation and hair follicle regeneration through TNF","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Teng, Y., Fan, Y., Ma, J., Lu, W., Liu, N., Chen, Y., Pan, W., and Tao, X. (2021). The PI3K\/Akt Pathway: Emerging Roles in Skin Homeostasis and a Group of Non-Malignant Skin Disorders. Cells, 10.","DOI":"10.3390\/cells10051219"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bai, R., Guo, Y., Liu, W., Song, Y., Yu, Z., and Ma, X. (2023). The Roles of WNT Signaling Pathways in Skin Development and Mechanical-Stretch-Induced Skin Regeneration. Biomolecules, 13.","DOI":"10.3390\/biom13121702"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105805","DOI":"10.1016\/j.isci.2022.105805","article-title":"Distinct bulge stem cell populations maintain the pilosebaceous unit in a \u03b2-catenin-dependent manner","volume":"26","author":"Han","year":"2022","journal-title":"iScience"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e35642","DOI":"10.1097\/MD.0000000000035642","article-title":"Identification of biomarkers of acne based on transcriptome analysis and combined with network pharmacology to explore the therapeutic mechanism of Jinhuang ointment","volume":"102","author":"Li","year":"2023","journal-title":"Medicine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/jocd.12934","article-title":"Serum interleukin-17 as a novel biomarker in patients with acne vulgaris","volume":"18","author":"Ebrahim","year":"2019","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/derm.15331","article-title":"Isotretinoin and FoxO1: A scientific hypothesis","volume":"3","author":"Melnik","year":"2011","journal-title":"Dermato-Endocrinology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2138691","DOI":"10.1080\/09546634.2022.2138691","article-title":"Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne","volume":"34","author":"Thiboutot","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1038\/s41598-018-22132-z","article-title":"Inhibitory effects of superoxide dismutase 3 on Propionibacterium acnes-induced skin inflammation","volume":"8","author":"Nguyen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jdv.18042","article-title":"Anti-drug antibodies of IL-23 inhibitors for psoriasis: A systematic review","volume":"36","author":"Norden","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_91","first-page":"403","article-title":"Adult atopic dermatitis: A review","volume":"151","author":"Napolitano","year":"2016","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/joim.13495","article-title":"Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial","volume":"292","author":"Brun","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/exd.14114","article-title":"Biomarkers in melanoma and non-melanoma skin cancer prevention and risk stratification","volume":"31","author":"Trager","year":"2022","journal-title":"Exp. Dermatol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/4\/186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:21:24Z","timestamp":1760106084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/4\/186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cimb46040186"],"URL":"https:\/\/doi.org\/10.3390\/cimb46040186","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]}}}